Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) Mazieres, J., Tomasini, P., Lusque, A., Boucekine, M., Gautschi, O., Cortot, A. B., Couraud, S., Thai, A., Ng, T., Greillier, L., Veillon, R., Neal, J. W., Popat, S., Gounant, V., Mhanna, L., Drilon, A., Baron, J., Barlesi, F. ELSEVIER. 2020: S826–S827
View details for DOI 10.1016/j.annonc.2020.08.1593
View details for Web of Science ID 000573469101565